ADHD Research News
New ADHD research studies referenced in this week's ADHD in the News:
- Childress, Ann. "Growth trajectories of youth with attention-deficit/hyperactivity disorder treated with delayed-release/extended-release methylphenidate: a pilot database analysis of real-world data." Poster 1596317, presented at Psych Congress 2023, Nashville, TN, September 6-10, 2023.
- DeCoster, Mikaela M., et al. "Pediatric ADHD Medication Errors Reported to United States Poison Centers, 2000 to 2021." Pediatrics (2023): e2023061942. DOI: 10.1542/peds.2023-061942.
- Dobrosavljevic, Maja, Henrik Larsson, and Samuele Cortese. "The diagnosis and treatment of attention-deficit hyperactivity disorder (ADHD) in older adults." Expert Review of Neurotherapeutics 23, no. 10 (2023): 883-893. DOI: 10.1080/14737175.2023.2250913.
Trends in Stimulant Prescription Fills Among Commercially Insured Children and Adults—United States, 2016-2021
Morbidity and Mortality Weekly Report, March 31, 2023
Centers for Disease Control and Prevention
What is already known about this topic?
Prescriptions for stimulants, primarily used to treat attention-deficit/ hyperactivity disorder (ADHD), were increasing for adults before the COVID-19 pandemic. Policies enacted during the pandemic expanded access to prescription stimulants via telehealth.
What is added by this report?
The percentage of adolescent and adult females and adult males receiving prescription stimulant fills increased during 2016-2021, particularly during 2020-2021.
What are the implications for public health practice?
Growing recognition of ADHD in adults and increases in prescription stimulant fills raise questions about current adult ADHD care. Development of clinical recommendations for diagnosing and managing adult ADHD could help guide safe and appropriate stimulant prescribing. Evaluation of policies enacted during the pandemic could identify benefits and harms of those policies.